Ana holds her PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL). She has worked in the T-cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, and has served as a scientific reviewer for the peer-reviewed journal Infection & Immunity.
A new study on a potential regulation mechanism of autoimmunity and anti-tumor immunity entitled “CEACAM1 regulates TIM-3-mediated tolerance and exhaustion” was published in Nature by Yu-Hwa Huang, part of Dr. Richard ... Read more
New insights into gut bacteria and their connection to metabolic syndrome have been uncovered by scientists. A study on Metabolic syndrome entitled “Intestinal Epithelial Cell Toll-like Receptor 5 Regulates the ... Read more
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics from its cannabinoid product platform and that commercialized the world’s first plant-derived cannabinoid prescription drug Sativex® ... Read more
Receptos, Inc., a San Diego-based biotechnology company, announced promising new clinical data for its drug candidate RPC1063 for ulcerative colitis. The drug was first discovered and synthesized at The Scripps Research Institute (TSRI) by ... Read more
A new study, entitled “Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death” published in the journal Proceedings of the National Academy ... Read more
A recent review on inflammatory bowel disease (IBD) entitled “Advances in IBD Genetics” was published in Nature Reviews Gastroenterology & Hepatology by Johan Van Limbergen, M.D., FRCPCH, Ph.D., assistant professor and clinician ... Read more
According to a recent study, prolonged treatment with Adalimumab, a TNF inhibiting anti-inflammatory drug, is beneficial for patients with moderately to severely active ulcerative colitis (UC). The study was conducted at the University ... Read more